CEO Eyal Barad and Dr. David Sans from Cannabics Pharmaceuticals in NYC, to Participate at Benzinga's Cannabis Capital Conference
Cannabics Pharmaceuticals Inc. (CNBX) announced participation in Benzinga's Cannabis Capital Conference in NYC on October 14-15, 2021. CEO Eyal Barad and Dr. David Sans will represent the company, highlighting its focus on developing cancer-related cannabinoid-based medicines. Cannabics is licensed in Israel to conduct scientific and clinical research on cannabinoid formulations. Interested parties can contact CEO Eyal Barad via email. For more updates about Cannabics, visit their website or follow them on social media.
- None.
- None.
TEL AVIV, Israel and BETHESDA, Md., Oct. 14, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that CEO Eyal Barad and Dr. David Sans FAARM, PhD, MBA in New York, will participate at the upcoming Benzinga's Cannabis Capital Conference in NYC on 14-15 of October. Parties interested in contacting Cannabics Pharmaceuticals, CNBX, should contact CEO Eyal Barad at eyalbarad@cannabics.com.
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.
Read more:
Recent expansion of Cannabics Pharmaceuticals' Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.).
Recent expansion of Cannabics Pharmaceuticals' Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.
Disclaimer:
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.
Logo - https://mma.prnewswire.com/media/796838/Cannabics_Pharmaceuticals_Logo.jpg
For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
+1 (877) 424-2429
info@cannabics.com
Related Links https://www.cannabics.com
View original content:https://www.prnewswire.com/news-releases/ceo-eyal-barad-and-dr-david-sans-from-cannabics-pharmaceuticals-in-nyc-to-participate-at-benzingas-cannabis-capital-conference-301400231.html
SOURCE Cannabics Pharmaceuticals Inc.
FAQ
What is Cannabics Pharmaceuticals' stock symbol?
When is Cannabics Pharmaceuticals participating in the Benzinga Cannabis Capital Conference?
Who from Cannabics Pharmaceuticals will attend the Benzinga Conference?
Where will the Benzinga Cannabis Capital Conference be held?
How can I contact Cannabics Pharmaceuticals?
